Business

Announcement on Voluntary Disclosure of Positive Top-line Results from the International Multicenter Phase III Clinical Trial of Shuvozhe Monotherapy as First-line Treatment for EGFR exon20ins Non-small Cell Lung Cancer

Announcement on Voluntary Disclosure of Positive Top-line Results from the International Multicenter Phase III Clinical Trial of Shuvozhe Monotherapy as First-line Treatment for EGFR exon20ins Non-small Cell Lung Cancer

articleDizal (jiangsu) Pharmaceutical Co. Ltd. Class AMarch 22, 20263/news/announcement-on-voluntary-disclosure-of-positive-top-line-results-from-the-international-multicenter-phase-iii-clinical-trial-of-shuvozhe-monotherapy-as-first-line-treatment-for-egfr-exon20ins-non-small-cell-lung-cancer
Announcement on Voluntary Disclosure of Positive Top-line Results from the International Multicenter Phase III Clinical Trial of Shuvozhe Monotherapy as First-line Treatment for EGFR exon20ins Non-small Cell Lung Cancer

About this update from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A

Announcement on Voluntary Disclosure of Positive Top-line Results from the International Multicenter Phase III Clinical Trial of Shuvozhe Monotherapy as First-line Treatment for EGFR exon20ins Non-small Cell Lung Cancer The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A